Dog,

IMO Cardiogenics' failure to execute operationally explains why the share price has fallen. If one accepts this premise, then nothing "strange" about the 3 quarter trend for revenue from sales of beads. Until Cardiogenics completes scientifically valid studies that demonstrate their beads enable IVD devices to produce superior results, then no third party vendor utilizing currently available beads will want/need the silver coated beads.

As for the analyzer, IMO the IRB for the four hospitals and relevant regulatory authorities informed Cardiogenics that IVD devices to be studied in the head-to-head study and subsequent larger clinical trial need to be manufactured to device specifications by a cGMP compliant manufacturer. A logical explanation for the INO announcement.

Cardiogenics' continued failure to properly inform their current and potential investors is IMO a clear failure to meet their financial obligations as a publicly traded company.

Ante